Fulcrum Therapeutics Valuation
| FULC Stock | USD 3.96 0.22 5.26% |
At this time, the firm appears to be undervalued. Fulcrum Therapeutics shows a prevailing Real Value of $4.73 per share. The current price of the firm is $3.96. Our model computes the value of Fulcrum Therapeutics from reviewing the firm fundamentals such as Profit Margin of (0.25) %, shares outstanding of 53.94 M, and Current Valuation of (28.02 M) as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Fulcrum Therapeutics' valuation include:
Price Book 0.8553 | Enterprise Value | Enterprise Value Ebitda (3.09) | Price Sales 2.762 | Enterprise Value Revenue 117.3999 |
Undervalued
Today
Please note that Fulcrum Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Fulcrum Therapeutics is based on 3 months time horizon. Increasing Fulcrum Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Fulcrum Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Fulcrum Stock. However, Fulcrum Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.96 | Real 4.73 | Target 5.67 | Hype 3.96 | Naive 4.39 |
The real value of Fulcrum Stock, also known as its intrinsic value, is the underlying worth of Fulcrum Therapeutics Company, which is reflected in its stock price. It is based on Fulcrum Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Fulcrum Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Fulcrum Therapeutics helps investors to forecast how Fulcrum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fulcrum Therapeutics more accurately as focusing exclusively on Fulcrum Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Fulcrum Therapeutics' intrinsic value based on its ongoing forecasts of Fulcrum Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Fulcrum Therapeutics' closest peers. If more than one evaluation category is relevant for Fulcrum Therapeutics we suggest using both methods to arrive at a better estimate.
Fulcrum Therapeutics Cash |
|
Fulcrum Valuation Trend
Comparing Fulcrum Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Fulcrum Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Fulcrum Valuation Data Drivers
Fulcrum Therapeutics Total Value Analysis
Fulcrum Therapeutics is currently expected to have valuation of (28.02 M) with market capitalization of 225.46 M, debt of 10.82 M, and cash on hands of 221.79 M. The negative valuation of Fulcrum Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Fulcrum Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(28.02 M) | 225.46 M | 10.82 M | 221.79 M |
Fulcrum Therapeutics Investor Information
About 90.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulcrum Therapeutics recorded a loss per share of 0.29. The entity had not issued any dividends in recent years. Based on the key indicators related to Fulcrum Therapeutics' liquidity, profitability, solvency, and operating efficiency, Fulcrum Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Fulcrum Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fulcrum Therapeutics has an asset utilization ratio of 1.09 percent. This indicates that the Company is making $0.0109 for each dollar of assets. An increasing asset utilization means that Fulcrum Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Fulcrum Therapeutics Ownership Allocation
Fulcrum Therapeutics holds a total of 53.94 Million outstanding shares. The majority of Fulcrum Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fulcrum Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fulcrum Therapeutics. Please pay attention to any change in the institutional holdings of Fulcrum Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fulcrum Therapeutics Profitability Analysis
The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with profit before overhead, payroll, taxes, and interest of 7.36 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Fulcrum Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Fulcrum Therapeutics and how it compares across the competition.
About Fulcrum Therapeutics Valuation
The stock valuation mechanism determines Fulcrum Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Fulcrum Therapeutics. We calculate exposure to Fulcrum Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fulcrum Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.2 M | 5.1 M | |
| Pretax Profit Margin | (39.91) | (37.91) | |
| Operating Profit Margin | (45.37) | (43.10) | |
| Net Loss | (39.91) | (37.91) | |
| Gross Profit Margin | 0.71 | 0.81 |
Fulcrum Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 61.3 M |
Fulcrum Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Fulcrum Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Fulcrum we look at many different elements of the entity such as Fulcrum's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Fulcrum Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Fulcrum Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Fulcrum Therapeutics' worth.Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |